行情

NTLA

NTLA

Intellia
NASDAQ

实时行情|Nasdaq Last Sale

12.47
+0.57
+4.79%
盘后: 12.47 0 0.00% 16:00 04/08 EDT
开盘
12.06
昨收
11.90
最高
12.49
最低
11.76
成交量
49.88万
成交额
--
52周最高
19.00
52周最低
9.18
市值
6.30亿
市盈率(TTM)
-5.9229
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NTLA价格均价为25.75,最高价位57.50,最低价为16.00。

EPS

NTLA 新闻

更多
  • 沪指横盘震荡 标普500暂时脱离“技术性熊市”
  • 新浪财经 · 17分钟前
  • 欧盟:英国计划在12月前达成贸易协议不切实际
  • 中国新闻网 · 1小时前
  • 沙特与俄罗斯开会磋商减产 美国敲边鼓旁观
  • 新浪财经综合 · 1小时前
  • 趣店跨界做奢侈品电商 百亿补贴引流背后前景难料
  • 投中网 · 1小时前

所属板块

生物技术和医学研究
+3.06%
制药与医学研究
+2.82%

热门股票

代码
价格
涨跌幅

NTLA 简况

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
展开

微牛提供Intellia Therapeutics Inc(NASDAQ-NTLA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NTLA股票新闻,以帮助您做出投资决策。